Assessment of the Biodistribution and Safety of [18F]MNI-968 in Healthy Subjects
- Registration Number
- NCT03142724
- Lead Sponsor
- Molecular NeuroImaging
- Brief Summary
The overall goal of this protocol is to evaluate the biodistribution of \[18F\]MNI-968 as a D1 receptor targeted radiopharmaceutical.
- Detailed Description
The overall goal of this protocol is to evaluate the biodistribution of \[18F\]MNI-968 as a D1 receptor targeted radiopharmaceutical. The specific objectives are:
* To determine the radiation dosimetry of \[18F\]MNI-968
* To assess the safety and tolerability of a single dose of \[18F\]MNI-968
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 6
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description [18F]MNI-968 [18F]MNI-968 To assess the safety and tolerability and to determine the radiation dosimetry of \[18F\]MNI-968.
- Primary Outcome Measures
Name Time Method Whole body tomographic PET images will be obtained for 6 healthy volunteers, and reviewed visually for assessment of body organ distribution of radioactivity. 2 Months Volumes of interest (VOI) will be placed on the visually identified source organs, and subsequently used for all the study PET frames. Activity within these volumes of interest is expressed in units of total radioactivity (kBq). Radioactivity will be corrected for body attenuation, but not for decay, and time activity data (TAC) generated for each source organ.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Molecular NeuroImaging, LLC
🇺🇸New Haven, Connecticut, United States